resili valu option upgrad outperform
august
group portfolio prove resili forecast increas despit weaker
macro stock weak valuat appeal manag
focu portfolio optimis provid addit option upgrad outperform
increas target price
dupont share fallen ytd under-perform qualiti us european chemic
stock diversifi valuat look compel
ev/ebitda yield despit weaker macro environ dupont prove
resili thank qualiti portfolio cost effici initi like manag
transpar capit alloc polici best owner approach portfolio
immun end market cost measur synergi come
thank proactiv cost cut beat margin despit revenu miss fear
guidanc cut compani rais ep guidanc despit cut top-lin expect
consensu ebitda ep compani guidanc
midpoint look realist vs upgrad
portfolio chang big small add free option
dupont commit divest non-cor busi valu includ
affili group also open monetis part portfolio four core
segment enjoy market-lead posit think manag opportun make
strateg move ad option alreadi attract sotp recent bloomberg
report suggest potenti sale nutrit bioscienc valu cite
givaudan kerri dsm interest parti see givaudan dsm like
partner deal materialis although neither option simpl would question
time given recent de-rat mani ingredi peer think transact would
shareholder-friendli given manag focu track record sharehold valu
exan bnpp estim thomson reuter consensu list currenc dividend reinvest yearli averag price fy end
date time london time invest recommend finalis may differ date time broad dissemin
websit appendix analyst certif import disclosur non-u research analyst disclosur
dupont chart
upgrad outperform resili portfolio
invest case valuat risk
compani profil financi highlight
dupont chart
figur dupont chart
sale divis pf
sale end market
ebitda divis
sale geographi pf
ebitda margin divis
upgrad outperform resili portfolio
upgrad dupont outperform neutral target price share
fallen ytd under-perform qualiti name us european
chemic even under-perform cyclic chemic throughout
dowdupont merger process subsequ spin-off dupont proven resili
despit volatil macro environ group high qualiti portfolio run
sharehold friendli manag team find valuat highli compel
share trade ev/ebitda yield
figur dupont under-perform qualiti diversifi chemic
dupont share price perform vs qualiti chem gase
dupont share price perform vs diversifi chemic
consum coverag
coverag
think portfolio resili best demonstr latest result
thank robust product measur beat margin despit top-lin miss
previous worri downsid risk guidanc given manag
optimist outlook auto smartphon think risk diminish
manag cut top-lin guidanc moder impli end
market assumpt despit manag abl maintain lower end
ebitda guidanc rang even upgrad ep guidanc consensu
expect look reason consensu ebitda ep
ebitda guidanc around ep
extent think write alreadi wall cut top-lin
guidanc manag previous guid recoveri auto
smartphon still see improv smartphon
driven product launch increas dupont content per unit howev dupont
longer expect acceler auto group level dupont guid
sale slightli y/i previous
figur exan bnpp division estim vs consensu guidanc
figur exan bnpp division estim vs consensu guidanc
best class margin profil
dupont pro forma ebitda margin well mani specialti
chemic compani europ us given conglomer complex
natur dupont portfolio struggl find real peer howev
benchmark dupont vs peer divis divis basi find division
margin peer across divis except transport
industri victrex distort peer averag margin worth
bear mind dupont maintain rel lean corpor structur
corpor cost sale refer diversifi chemic compani
usual run corpor cost sale
figur benchmark analysi dupont division ebitda margin vs
peer averag detail given division section
synergi product measur support margin expans
manag implement aggress synergi sinc dowdupont merger
close two year ago dupont also initi number separ cost initi
respons weaker macro environ combin
support margin expans
figur dupont target synergi end plu addit cost save
cumul synergi stand-alone dupont
focu cash convers capital-expenditure disciplin
mid-term manag target convers net incom post
amortis annual improv manag incent
link well sale ebitda metric dupont explicit polici
return excess cash sharehold via buyback buy-back authoris
june complet end
like manag disciplin approach capital-expenditure select growth
project undertaken manag target capital-expenditure spend sale
mainten larg capital-expenditure project cost
notabl larg invest includ invest new tyvek capac safeti
construct kapton/pyralux capac electron imag dupont
complet probiot expans us nutrit bioscienc
big small portfolio move sharehold friendli
earli merger integr process dupont commit divest
portfolio target acceler top-lin growth
improv oper margin divest dupont
creat separ non-cor divis identifi ebitda non-
core equival group earn asid expect dispos
non-cor asset could see dupont monetis part portfolio
accord bloomberg dupont may evalu option nutrit
bioscienc divis portfolio includ sale spin revers morri trust
process explain page valu nutrit bioscienc
ebitda nearli valu quot articl
discuss later note think headlin come surpris
sale nutrit wide specul throughout dowdupont merger
process importantli think transact would sharehold friendli
dupont standpoint given manag focu track record sharehold
gener like manag practic unemot approach portfolio
manag non-cor busi simpli identifi busi
lower growth/margin/return profil simpli busi dupont may
best owner think dupont could appli approach larger portfolio move
beyond non-cor segment quot execut chairman ed breen recent
confer realli path creat signific valu sharehold
transact would definit look
would argu best owner reason could appli core
divis nutrit bioscienc four core divis run
independ respons spend etc given
lead market posit divis would probabl larg enough oper
stand-alone compani exampl spin-off scenario partner
anoth player execut chairman ed breen said earlier year
definit studi option avail us someth els
way creat signific long-term valu sharehold
shi pursu path also kind give us lot option creat
valu move next year
show sotp analysi follow page
manag portfolio manag track record
note ed breen well known corpor action tenur chairman
ceo tyco intern tenur oversaw
signific restructur includ chang entir board mani top
execut busi split three public trade compani tyco
tyco healthcar covidien later bought
tyco electron nyse list te connect tyco intern
later split three new entiti nyse list revers morri trust transact
tyco control tyco fire secur merg
johnson control
target price deriv dcf analysi cross referenc sotp
analysi detail
origin entegri versum deal multipl merck versum post synergi
sale agre gyru capit privat equiti feb run exist manag expect close juli
sale indorama announc oct pend approv
exan bnp pariba estim regard peer bold includ peer multipl refer
valu
chang estim
make minor chang estim note upgrad ebitda
ep reflect lower interest cost guid compani
rais target price within divis increas
estim electron imag partli off-set lower estim transport
industri non-cor divis
figur summari dupont quarterli financi
net incom continu
option outsid dilut
next section given mani corpor chang sinc dowdupont
merger analys divis turn particular emphasi
nutrit bioscienc given recent bloomberg headlin suggest potenti
sale busi also opportun spend time
nutrit bioscienc manag team global headquart copenhagen
june year
nutrit bioscienc largest divis within dupont revenu although
lowest ebitda margin divis provid ingredi food
beverag dietari supplement pharma home person care bioethanol
anim feed market busi predominantli compris legaci dupont
asset includ danisco acquir also includ pharma
food microbi control health nutrit swap
dupont crop protect condit dowdupont merger divis
global headquart locat copenhagen denmark
sale subdivis
sale geographi
busi report non-cor
given divis divers busi mix profit vari significantli product
 bioscienc exampl dupont cultur enzym peer chr
hansen novozym print ebitda margin low mid wherea peer
food beverag space print mid-teen margin recent spent time
nutrit bioscienc manag team headquart copenhagen
event manag confirm divis margin top quartil
rel peer across individu ingredi product line
run benchmark analysi base compani identifi peer
figur dupont nutrit bioscienc ebitda margin rel peer
dupont broad ingredi portfolio
figur summari dupont nutrit bioscienc portfolio
soy pea protein
function ingredi eg stabilis
probiot dietari supplement food
oligosaccharid infant formula
enzym bioethanol laundri deterg food
exan bnp pariba estim address market base dupont estim
new segment combin bioscienc
dupont updat segment report structur june within nutrit
bioscienc divis dupont combin probiot cultur etc
industri bioscienc togeth vs previou structur nutrit
separ industri bioscienc accord ceo marc doyl recent
interview move primarili consolid across enzym cultur
platform think nuanc chang ultim chang overal
division structur like day day oper worth note mani
potenti strateg partner per bloomberg specul would signific
strateg interest busi strateg interest bioscienc
near term trend strong growth bioscienc weak
dupont report doubl digit growth probiot outperform peer chr
hansen although extent think impact dupont capac
ramp time order dupont recent complet capac
expans rochest new york increas dupont probiot capac
bioactiv enzym remain pressur due weak market dynam
us bioethanol expect flag peer novozym would
expect trend continu food beverag volum declin
driven weak function ingredi dairi market expect
recov toward low singl digit top-lin growth
sale wide specul
note think manag could consid strateg option valu
creation four core divis strong player relev
market run independ howev specul date
centr nutrit bioscienc divis divis exposur
nutrit end market busi limit overlap henc fewer synergi
rest dupont portfolio rest group exposur
industri end market overlap across divis across
auto construct electron think best owner principl one could
argu busi could benefit synergi combin peer
ingredi space creat integr solut offer simpli
quot european market ingredi stock trade premium
peer us smaller sampl size list ingredi stock
accord recent bloomberg articl dupont said explor option
rang sale spin-off revers morri trust transact
discuss greater depth follow section nutrit bioscienc
figur european specialti ingredi trade premium us specialti
novozym symris us ingredi basket includ sensient
 new topic ingredi sector
alreadi rel high level activ ingredi sector
includ exampl iff acquisit frutarom givaudan acquisit
naturex ingredi confer march survey corpor
attend varieti topic includ find survey
found consum ingredi confer feedback grow acquir
survey corpor major respond highlight
prioriti use cash expect sector next
month mani highlight prefer broad portfolio exposur
adjac highlight merit divers portfolio opportun offer
integr solut custom
figur result survey corpor attend exan bnp pariba consum ingredi
confer march
prioriti term use cash
prioriti term use cash
expect see sector next
look adjac vs year ago
better focus broader portfolio
would will rais equiti right deal
topic nutrit bioscienc also came meet ingredi
corpor annual ceo confer june see feedback
dsm givaudan kerri specul interest partner
potenti sale hot topic amongst investor corpor
throughout whole dowdupont merger process neither recent bloomberg
headlin list potenti partner mention come surpris
tax reason limit scope larger transact septemb
would mark two year point complet dowdupont
merger accord articl dupont yet held formal talk potenti
suitor bloomberg stori may also illicit interest parti mention
articl discuss potenti merit combin compani
mention other detail nutrit bioscienc section note
valu nutrit bioscienc ebitda use
weight averag peer trade multipl nearli quot
bloomberg articl given size deal struggl think
counterparti could afford acquir entir busi outright therefor
believ deal would like structur revers morri trust rmt
revers take-over break
rmt would still complex natur would requir acquir will
combin entiti detail basic step rmt
anyon familiar type transact see ad complex
potenti deal potenti partner financi
firepow would see strateg merit merg entir busi
easili identifi number corpor would want buy select
asset within portfolio ultim hard assess financi merit
potenti rmt vs altern strateg option vs deal without understand
potenti tax implic straight sale process
figur ingredi player headroom outright acquisit
balanc sheet headroom across ingredi space fund gap base valuat
pf
pf
gap
mcap
revers morri trust
revers morri trust rmt transact involv tax free spin-off busi
own us list entiti immedi follow revers take-over new
entiti rmt partner allow compani sell asset without incur tax
oblig gain aris sale transact fairli
complex look preced deal transact taken place two
us list compani howev possibl transact take place
us non us compani
lay basic step transact
compani spun potenti split sharehold
distribut compani would requir approv board director
acquir compani merg compani use share
consider distribut compani sharehold receiv stock acquir
compani must end own least outstand acquir
compani stock thu process effect becom revers take-over
possibl reduc equiti valu compani
distribut compani sharehold substanti minimum
requir achiev ad debt compani
proce go distribut compani sharehold via
special dividend addit debt stay acquir
transact would like requir approv acquir compani
one exampl transatlant transact rmt london list micro
focu hewlett packard entepris softwar divis seen
exampl us rmt chemic space merger
chlor-alkali busi merger georgia gulf commod
chemic creat axial current dupont execut chairman ed breen
also behind rmt transact tyco control
givaudan interest parti ex bioscienc
compani
givaudan market leader flavour sale fragranc
recent gone number adjac via acquisit naturex
ceo gill andrier fairli vocal willing larg deal
strateg rational simpli sake size busi complet
number bolt-on date includ naturex although recent ceo
confer manag confirm could also contempl larg deal say
note one opportun magnitud
believ givaudan would interest part portfolio
primarili probiot cultur one highest growth highest margin
part busi note givaudan exposur probiot
today except small exposur microbi skincar although player
symris kerri expand segment recent year via
acquisit think could strateg fit dupont food beverag
part givaudan integr solut strategi suppli custom
flavour
believ givaudan would interest industri bioscienc
busi confirm ceo confer pharma busi
would overlap givaudan exist busi
givaudan good track record integr acquisit oper asset
see potenti sale synergi integr solut approach expand
beyond givaudan flavour offer function ingredi probiot food
enzym cultur like overlap exist custom
synergi would limit
would synergi bioscienc busi bioethanol anim
feed thu see givaudan acquir particular asset
would expect signific anti-trust issu limit overlap
ingredi portfolio today
board director dispos condit capit maximum aggreg
amount
note cascad invest gate own givaudan dupont
partner melinda gate foundat variou project exampl
probiot treat sepsi bangladesh grant therapeut protein develop
think key givaudan sharehold may avers
sharehold combin compani
compani
dsm nutrit life scienc compani exposur human nutrit anim
nutrit materi
see strateg overlap dsm nutrit dupont nutrit bioscienc
dsm actual own equiti stake danisco latter acquir
dupont
follow number non-cor divest success restructur plan dsm
significantli reduc leverag net debt/ebitda dsm
cost save phase back agenda alongsid organ invest
manag express interest explor inorgan growth opportun
evolv portfolio predominantli nutrit although compani rhetor
focus bolt-on acquisit rather larg transform
detail think clear strateg rational synergi
opportun combin dsm dupont nutrit bioscienc howev
note dsm manag fairli risk avers approach
mix track record past deal manag also sent signal
balanc sheet disciplin buy-back dividend step earlier
year
combin dupont food beverag would add dsm alreadi divers
ingredi offer believ two busi complementari
exist dsm portfolio weight toward nutrit ingredi vitamin
miner etc wherea dupont food beverag portfolio weight toward
wonder whether would anti-trust issu cultur market
dsm current mainli dairi dietari supplement well behind chr hansen
dupont estim dupont dsm would global cultur
market par global leader chr hansen
unlik givaudan kerri see strateg overlap dsm dupont
industri bioscienc howev might conflict dsm year allianc
enzym leader novozym anim feed enzym dsm alreadi exist
posit enzym anim feed market lesser extent enzym
food bioenergi space novozym current suppli anim feed enzym
dsm also origin supplier bioethanol enzym dsm poet
ethanol plant although dsm poet announc plan build
in-hous capac latter dsm alreadi direct exposur food
enzym space via acquisit cargil busi
final think could strateg overlap dupont pharma solut
excipi busi dsm dietari supplement offer capsul solut
figur dsm nutrit ingredi orang could complement dupont function ingredi
figur dsm nutrit dupont end market
dsm nutrit end market
dupont end market
note see strateg rational deal across multipl part
portfolio therefor believ manag would abl identifi variou sale
cost synergi look back mix track record bolt-on deal dsm
necessarili overpay asset fail integr success problem
subsequ resolv cost save plan expect topic
integr abil realis synergi would come discuss
investor dsm announc deal
potenti divest materi busi materi repres roughli
dsm portfolio today would drop pro forma ebitda follow
deal scenario would expect dsm divest materi busi
focu sole nutrit activ could support re-rat toward nutrit
focus multipl mid-term dsm current trade ev/ebitda vs
ingredi averag
valu dsm materi busi
ev/ebitda divest materi plu signific re-gear would enough
dsm fund straight acquisit
manag board authoris issu ordinari share
exclud pre-empt right authoris issu addit
ordinari share connect right issu
assum valu dupont
scenario leverag
market cap
think potenti divest materi cant help draw
parallel dsm sold polyolefin busi sabic
shortli acquir roch vitamin busi similar valuat
foundat share would waiv note dsm also prefer
share foundat sticht independ legal entiti foundat
right issu cumul prefer share right acquir
capit issu form cum pref share less one
done without approv supervisori manag board
event like event take-over bid signific ordinari share stake build
event rmt transact foundat structur would need taken
account like waiv
assess potenti anti-trust note wonder whether would
potenti anti-trust issu cultur estim dupont dsm combin would
market share equival market leader chr hansen cultur would
make small part combin portfolio sub sale howev
attract market high growth rate high margin high barrier entri
wonder whether would conflict interest enzym ex-food
beverag portfolio given dsm long-standing year relationship novozym
anim feed lesser extent bioethanol dupont competitor
figur strateg overlap across portfolio small area anti-trust risk
global market share cultur market
global market share food bev enzym market
kerri interest parti ex bioscienc
compani
kerri compani broadest rang product ingredi space
also market leader integr solut
think combin kerri could make lot strateg sens given
complementari exposur two busi would add kerri exist
integr solut offer givaudan think kerri would limit
interest bioscienc part portfolio
kerri target focu four criteria tast health nutrit develop market
foodservic kerri compet dupont food beverag exampl
textur emulsifi protein solut well probiot ganeden
howev would expect signific anti-trust issu given divers rang
ingredi within segment
potenti deal would carri limit integr risk given kerri exist leadership
integr solut kerri alreadi infrastructur place doubl size
tast nutrit busi kerri typic highest bidder asset
howev although deal could final trigger dispos group
materi synergi would like term sale cost given kerri
exist structur believ compani would capabl extract sale
synergi much faster peer
co-op still hold small stake kerri willing particip
potenti rmt could question although unlik unsurmount
 ill-advis given frut never say never
compani
player tast scent nutrit recent acquisit frutarom
ad exposur number new adjac
note us player mention origin bloomberg articl
 peer givaudan combin dupont nutrit bioscienc
would support strateg shift toward integr solut combin flavour
function ingredi probiot etc see limit overlap
bioscienc pharma busi
think hope interest limit group limit financi
oper capac follow acquisit frutarom process
integr bought despit recent unearth complianc
issu cant help feel wait instead rush
buy frutarom hand larg deal like could way divert
market attent away recent woe frutarom adjust capit
structur combin entiti current leverag net debt/ebitda post
frutarom also perceiv manag partli motiv size
could see theoret sale synergi cross sell per frutarom
deal leverag custom relationship compani howev see risk
materi disrupt add anoth monument integr programm
top already-complex frutarom project oper cost synergi would
would synergi bioscienc busi bioethanol anim
would need convinc major sharehold winder benefit
transact winder built stake averag price current share
price
implic player
bloomberg stori may also illicit interest parti mention
articl discuss compani think may may
interest asset
basf transform deal unlik
past given size exposur nutrit basf
mention logic potenti acquir space howev note
manag repeatedli rule make transform acquisit
would assum interest would reduc face
macro pressur need balanc signific capital-expenditure larg dividend
vulner credit rate basf yet demonstr valu creation acquisit
bayer asset last year largest acquisit ever made group
get sharehold vote favour larg transact seem unlik
basf nutrit divis gener group sale exposur
aroma ingredi anim human nutrit pharma excipi person
would consid basf buyer last resort smaller unwant asset
presum favour multipl exampl note player
givaudan kerri would interest bioscienc busi
asset would offer relev strateg overlap basf basf small
exposur mainli industri enzym exampl anim feed household care
acquir henkel portfolio valu dupont industri bioscienc
microbi control busi ebitda line global
becom activ acquir ingredi space group
long-standing expertis textur function nutrit enter flavour
industri acquisit wild flavour creat
dedic nutrit segment consist anim nutrit bioactiv wild
flavour specialti ingredi aim creat one-stop-shop
custom total market cap nutrit divis roughli
sale note group sale group net debt/ebitda
ratio current base consensu estim
announc number deal nutrit space past year
includ wild flavour bought reportedli premium multipl
ltm ebitda recent bought neovia ebitda smaller
bolt-on probiot intern ebitda well number small bolt-
on primarili flavour recent flurri deal suggest remain will
increas exposur nutrit market sometim premium multipl
clear interest probiot well flavour capabl
see complementar bioscienc busi alreadi exposur
anim feed amino acid recent probiot neovia acquisit
also produc bioethanol exist partnership dupont
industri bioscienc develop produc cellulos enzym bioethanol
product ethanol wonder whether might conflict interest
risk disynergi bioethanol enzym howev compet
bioethanol produc would exist dupont custom also see
overlap food beverag exampl protein ingredi soy pea protein
function ingredi hydrocolloid emulsifi
symris futur target acquir
symris list flavour fragranc major mention
press specul market cap net debt/ebitda symris
limit firepow particip larg deal manag express
limit interest big multipl elev organ growth stori
remain strong givaudan see limit overlap bioscienc
pharma segment
hand tabl turn dupont becom acquir
rather seller ingredi asset think symris could attract target
dupont note danisco sold sub-scal flavour busi peer
firmenich year danisco bought dupont ad
flavour today would support wider industri move toward integr solut
firmenich nr firepow big deal
firmenich global player flavour fragranc highlight
 name see strateg rational combin flavour
support integr solut offer howev privat famili ownership
transform deal note firmenich acquir danisco flavour busi
ev/sal time
firepow willing
execut
read across chr hansen novozym
domin player cultur enzym respect scope
chr hansen novozym particip deal includ dupont health
bioscienc busi due anti-trust issu see strateg rational either
player particip deal involv remain part dupont chr
hansen novozym manag team note past corpor
chang danisco necessarili materi impact competit
landscap asid danisco disrupt earli day integr
dupont would expect signific impact ownership chang
howev worth note disrupt deal could opportun
player gain market share resourc
electron imag gener roughli dupont group sale ebitda
margin highest margin busi group produc materi
involv product semiconductor integr chip print circuit board
display applic increas complex devic product process
support market growth spend group averag sale
sale subdivis
sale end market
sale geographi
exan bnp pariba estim note end market geograph sale split includ busi report non core
busi includ legaci dupont electron legaci
electron materi manag consolid geograph footprint
 activ increas invest weight toward asia incl spend
earlier month dupont announc manag chang appoint jon kemp
presid divis kemp also continu current role presid
non-cor segment former head legaci dupont electron
commun succeed jim fahey head divis sinc merger
previous head electron materi
competitor includ electron materi compani merck
kga plu versum note electron
materi industri go wave consolid acquisit
versum merck respons initi merger equal arrang
versum origin moe agreement versum
announc januari impli multipl ebitda follow counterbid
merck march final takeout multipl versum pre synergi
deal expect close wonder whether dupont would
interest get involv industri consolid tie
corpor chang dowdupont
figur dupont ebitda margin rel peer
exan bnp pariba estim base estim disclos compani
near term trend smartphon launch cost initi support
volum hamper on-going inventori correct memori
semiconductor space despit weak smartphon market dupont expect
support new smartphon launch claim reason
visibl benefit increas content per unit
initi also step divis least cost
initi implement ytd howev expect step primarili
dupont safeti construct global leader engin solut use
water shelter safeti applic divis includ key brand kevlar
nomex aramid high strength fibr made polyamid
use personnel protect medic devic auto aerospac oil ga
materi use personnel protect medic packag waterproof roof
sale subdivis
sale end market
sale geographi
exan bnp pariba estim note geograph end market sale split includ busi report non core
dupont divis aggress implement cost initi
ebitda margin y/i think major initi
implement would expect limit sequenti margin
increas
particularli hard benchmark due limit direct peer limit
disclosur dupont list dsm honeywel kingspan purolit
